CytoPathfinder, a Japanese startup developing microarrays and drug-delivery technologies, last week said that Qiagen will supply it siRNAs for use on its transfection microarray for high-throughput RNAi screening.

CytoPathfinder said the deal not only gives it access to Qiagen's HiPerformance siRNA design algorithm, which it licensed from Novartis in late 2003 (see RNAi News, 12/19/2003), but a partner with a global reach — something that could prove vital for the Japanese startup as it eyes overseas markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.